| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/S1474-4422(07)70329-0 |
| P698 | PubMed publication ID | 18178525 |
| P2093 | author name string | Hans-Peter Hartung | |
| Pieter A van Doorn | |||
| Peter Donofrio | |||
| Vera Bril | |||
| Ingemar S J Merkies | |||
| Marinos C Dalakas | |||
| Richard A C Hughes | |||
| Chunqin Deng | |||
| ICE Study Group | |||
| Kim Hanna | |||
| Norman Latov | |||
| P2860 | cites work | Plasma exchange for chronic inflammatory demyelinating polyradiculoneuropathy | Q24246631 |
| Psychometric evaluation of a new sensory scale in immune-mediated polyneuropathies. Inflammatory Neuropathy Cause and Treatment (INCAT) Group | Q33179842 | ||
| Connecting impairment, disability, and handicap in immune mediated polyneuropathies | Q33185473 | ||
| Intravenous immunoglobulin treatment in patients with chronic inflammatory demyelinating polyneuropathy: a double blind, placebo controlled study | Q33590410 | ||
| Intravenous immunoglobulin for chronic inflammatory demyelinating polyradiculoneuropathy. | Q34699002 | ||
| Chronic inflammatory demyelinating polyradiculoneuropathy: a prevalence study in south east England | Q35451141 | ||
| Comparison of electrodiagnostic abnormalities and criteria in a cohort of patients with chronic inflammatory demyelinating polyneuropathy. | Q35607913 | ||
| Chronic inflammatory demyelinating polyneuropathy. | Q36084472 | ||
| Randomized controlled trial of intravenous immunoglobulin versus oral prednisolone in chronic inflammatory demyelinating polyradiculoneuropathy. | Q43708051 | ||
| Properties of a new intravenous immunoglobulin (IGIV-C, 10%) produced by virus inactivation with caprylate and column chromatography | Q44386886 | ||
| Interobserver agreement in the assessment of muscle strength and functional abilities in Guillain-Barré syndrome | Q44643471 | ||
| High-dose intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyneuropathy: a double-blind, placebo-controlled, crossover study | Q45361840 | ||
| Chronic inflammatory demyelinating polyradiculoneuropathy. Clinical characteristics, course, and recommendations for diagnostic criteria | Q46619488 | ||
| Intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyneuropathy. A double-blind, placebo-controlled, cross-over study | Q48954233 | ||
| Diagnosis of CIDP | Q57406723 | ||
| Chronic relapsing polyneuritis | Q67444975 | ||
| A novel trial design to study the effect of intravenous immunoglobulin in chronic inflammatory demyelinating polyradiculoneuropathy | Q71817931 | ||
| Randomized controlled trial of IVIg in untreated chronic inflammatory demyelinating polyradiculoneuropathy | Q73550695 | ||
| Assessing grip strength in healthy individuals and patients with immune-mediated polyneuropathies | Q74199963 | ||
| Rapid infusion of intravenous immune globulin in patients with neuromuscular disorders | Q77162395 | ||
| European Federation of Neurological Societies/Peripheral Nerve Society Guideline on management of chronic inflammatory demyelinating polyradiculoneuropathy. Report of a joint task force of the European Federation of Neurological Societies and the Pe | Q81343947 | ||
| Pathogenesis of chronic inflammatory demyelinating polyradiculoneuropathy | Q82741985 | ||
| P433 | issue | 2 | |
| P921 | main subject | placebo | Q269829 |
| chronic inflammatory demyelinating polyradiculoneuropathy | Q1088030 | ||
| placebo-controlled trial | Q108853737 | ||
| P304 | page(s) | 136-144 | |
| P577 | publication date | 2008-02-01 | |
| P1433 | published in | Lancet Neurology | Q15755067 |
| P1476 | title | Intravenous immune globulin (10% caprylate-chromatography purified) for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy (ICE study): a randomised placebo-controlled trial | |
| P478 | volume | 7 |
| Q83232977 | 9 Human Immunoglobulins |
| Q82787442 | A new trick for an old dog: pulsed dexamethasone treatment for chronic inflammatory demyelinating polyneuropathy |
| Q51731817 | A randomised, multi-centre phase III study of 3 different doses of intravenous immunoglobulin 10% in patients with chronic inflammatory demyelinating polyradiculoneuropathy (ProCID trial): Study design and protocol. |
| Q38114834 | Acquired neuropathies |
| Q37918316 | Advances in the diagnosis, pathogenesis and treatment of CIDP. |
| Q37895536 | Advances in the treatment of chronic inflammatory demyelinating neuropathies in 2010. |
| Q81753387 | Advances in the use of IVIg in neurological disorders |
| Q30849110 | Aggregated N-of-1 trials for unlicensed medicines for small populations: an assessment of a trial with ephedrine for myasthenia gravis |
| Q34645179 | An update on the management of chronic inflammatory demyelinating polyneuropathy |
| Q37658338 | Anterior interosseous nerve syndrome: fascicular motor lesions of median nerve trunk |
| Q45277522 | Antibodies to gliomedin cause peripheral demyelinating neuropathy and the dismantling of the nodes of Ranvier. |
| Q39434973 | Autoantibodies in chronic inflammatory neuropathies: diagnostic and therapeutic implications. |
| Q35512273 | Autoimmune neuromuscular disorders in childhood |
| Q37901520 | Bringing immunoglobulin knowledge up to date: how should we treat today? |
| Q47978955 | CIDP and other inflammatory neuropathies in diabetes - diagnosis and management |
| Q55284498 | Challenges in the diagnosis of chronic inflammatory demyelinating polyneuropathy. |
| Q35714185 | Challenges of clinical trial design when there is lack of clinical equipoise: use of a response-conditional crossover design |
| Q91835771 | Chronic Inflammatory Demyelinating Polyneuropathy: Time to Maximal Recovery |
| Q84067083 | Chronic Inflammatory Demyelinating Polyradiculoneuropathy |
| Q28384089 | Chronic inflammatory demyelinating polyneuropathy |
| Q35950471 | Chronic inflammatory demyelinating polyneuropathy (CIDP): change of serum IgG dimer levels during treatment with intravenous immunoglobulins |
| Q37714082 | Chronic inflammatory demyelinating polyradiculoneuropathy: diagnostic and therapeutic challenges for a treatable condition |
| Q26823910 | Chronic inflammatory demyelinating polyradiculoneuropathy: from bench to bedside |
| Q90575546 | Clinical and economic comparison of an individualised immunoglobulin protocol vs. standard dosing for chronic inflammatory demyelinating polyneuropathy |
| Q37626126 | Clinical applications of intravenous immunoglobulins in neurology |
| Q90394386 | Combined intravenous immunoglobulin and methylprednisolone as induction treatment in chronic inflammatory demyelinating polyneuropathy (OPTIC protocol): a prospective pilot study |
| Q100416128 | Complement in neurological disorders and emerging complement-targeted therapeutics |
| Q38334722 | Corneal confocal microscopy in chronic inflammatory demyelinating polyneuropathy |
| Q33991742 | Cost-utility of Intravenous Immunoglobulin (IVIG) compared with corticosteroids for the treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in Canada |
| Q34620111 | Current proposed mechanisms of action of intravenous immunoglobulins in inflammatory neuropathies |
| Q59810481 | Depression with Chronic Inflammatory Demyelinating Polyneuropathy |
| Q35991588 | Deregulated Fcγ receptor expression in patients with CIDP. |
| Q38224784 | Diagnosis and treatment of chronic acquired demyelinating polyneuropathies |
| Q37118703 | Diagnostic accuracy of qualitative versus quantitative tuning forks: outcome measure for neuropathy |
| Q57300562 | Diagnostic insights into chronic-inflammatory demyelinating polyneuropathies |
| Q38137114 | Disease-modifying therapy in multiple sclerosis and chronic inflammatory demyelinating polyradiculoneuropathy: common and divergent current and future strategies |
| Q86421395 | Dosing and individualized treatment - patient-centric treatment: changing practice guidelines |
| Q39823028 | Economic Evaluation of Intravenous Immunoglobulin plus Corticosteroids for the Treatment of Steroid-Resistant Chronic Inflammatory Demyelinating Polyradiculoneuropathy in Thailand |
| Q86421453 | Effective dosing strategies for therapeutic immunoglobulin: managing wear-off effects in antibody replacement to immunomodulation |
| Q92567610 | Efficacy and Safety of Octagam® in Patients With Chronic Inflammatory Demyelinating Polyneuropathy |
| Q37542243 | Efficacy and safety of Privigen(®) in patients with chronic inflammatory demyelinating polyneuropathy: results of a prospective, single-arm, open-label Phase III study (the PRIMA study). |
| Q36484438 | Efficacy of Intravenous Immunoglobulin in Neurological Diseases. |
| Q56960415 | Efficiency of long-term treatment with intravenous immunoglobulins correlates with reduced autoreactive T cell responses in chronic inflammatory demyelinating polyneuropathy patients |
| Q43602613 | Electrophysiologic correlations with clinical outcomes in CIDP |
| Q35834424 | Elevated Vibration Perception Thresholds in CIDP Patients Indicate More Severe Neuropathy and Lower Treatment Response Rates |
| Q60699516 | European consensus proposal for immunoglobulin therapies |
| Q33385332 | Evidence for the use of intravenous immunoglobulins--a review of the literature |
| Q33666033 | Fatigue in neuromuscular disorders: focus on Guillain-Barré syndrome and Pompe disease |
| Q33353548 | First-line treatment for CIDP: a new piece of the puzzle |
| Q57190615 | Hypertension guidelines: How do they apply to kidney transplant recipients |
| Q49299297 | IVIg for apparently autoimmune small-fiber polyneuropathy: first analysis of efficacy and safety |
| Q38842992 | Immune Gamma Globulin Therapeutic Indications in Immune Deficiency and Autoimmunity |
| Q57476569 | Immune-mediated neuropathies |
| Q37339743 | Immunomodulation of inflammatory leukocyte markers during intravenous immunoglobulin treatment associated with clinical efficacy in chronic inflammatory demyelinating polyradiculoneuropathy |
| Q24201954 | Immunomodulatory treatment other than corticosteroids, immunoglobulin and plasma exchange for chronic inflammatory demyelinating polyradiculoneuropathy |
| Q24236599 | Immunomodulatory treatment other than corticosteroids, immunoglobulin and plasma exchange for chronic inflammatory demyelinating polyradiculoneuropathy |
| Q36365583 | Immunomodulatory treatment other than corticosteroids, immunoglobulin and plasma exchange for chronic inflammatory demyelinating polyradiculoneuropathy. |
| Q36484399 | Immunotherapies for Neurological Manifestations in the Context of Systemic Autoimmunity |
| Q36484418 | Immunotherapy in Peripheral Neuropathies |
| Q37140095 | Impaired inhibitory Fcgamma receptor IIB expression on B cells in chronic inflammatory demyelinating polyneuropathy |
| Q88155316 | Individualized immunoglobulin therapy in chronic immune-mediated peripheral neuropathies |
| Q46052200 | Inflammatory demyelinating neuropathies |
| Q83226673 | Inflammatory demyelinating neuropathies |
| Q85018724 | Intravenous IgG for treatment of neuromuscular diseases |
| Q24201573 | Intravenous immunoglobulin for chronic inflammatory demyelinating polyradiculoneuropathy |
| Q24240936 | Intravenous immunoglobulin for chronic inflammatory demyelinating polyradiculoneuropathy |
| Q35187840 | Intravenous immunoglobulin for chronic residual peripheral neuropathy in eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome): a multicenter, double-blind trial |
| Q38646013 | Intravenous immunoglobulin for maintenance treatment of chronic inflammatory demyelinating polyneuropathy: a multicentre, open-label, 52-week phase III trial |
| Q51785190 | Intravenous immunoglobulin for neuromuscular disease: costs, benefits and reimbursement. |
| Q37891769 | Intravenous immunoglobulin for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy: a systematic review and meta-analysis. |
| Q50133537 | Intravenous immunoglobulin for treatment of neuromuscular disease. |
| Q38308436 | Intravenous immunoglobulin in neurology--mode of action and clinical efficacy |
| Q37113332 | Intravenous immunoglobulin therapy for small fiber neuropathy: study protocol for a randomized controlled trial |
| Q37873722 | Intravenous immunoglobulin therapy in rheumatic diseases |
| Q43087483 | Intravenous immunoglobulin treatment in chronic neurological diseases: do we have maintenance dose right? |
| Q39618476 | Intravenous immunoglobulin versus intravenous methylprednisolone for chronic inflammatory demyelinating polyradiculoneuropathy: a randomised controlled trial |
| Q80454079 | Intravenous immunoglobulin: a first-line treatment in CIDP? |
| Q88363120 | Intravenous versus subcutaneous immunoglobulin - Authors' reply |
| Q33419638 | Is dosing of therapeutic immunoglobulins optimal? A review of a three-decade long debate in europe |
| Q92244120 | Long-term safety and efficacy of subcutaneous immunoglobulin IgPro20 in CIDP: PATH extension study |
| Q37737994 | Mechanisms of IVIG efficacy in chronic inflammatory demyelinating polyneuropathy. |
| Q49167761 | Minimum clinically important difference analysis confirms the efficacy of IgPro10 in CIDP: the PRIMA trial |
| Q35918784 | Modifying the Medical Research Council grading system through Rasch analyses |
| Q36691991 | Neurofascin-155 IgG4 in chronic inflammatory demyelinating polyneuropathy |
| Q93062975 | Neuroimaging markers of clinical progression in chronic inflammatory demyelinating polyradiculoneuropathy |
| Q55267080 | Neurological Disease in Lupus: Toward a Personalized Medicine Approach. |
| Q54935864 | Neurological manifestations of primary Sjögren's syndrome. |
| Q42775420 | New Frontiers in Subcutaneous Immunoglobulin Treatment |
| Q41173378 | New advances in the treatment of neurological diseases using high dose intravenous immunoglobulins |
| Q37507924 | Newer therapeutic options for chronic inflammatory demyelinating polyradiculoneuropathy |
| Q47126672 | Novel pathomechanisms in inflammatory neuropathies |
| Q88001088 | Octagam® for chronic inflammatory demyelinating polyneuropathy: results from three observational studies |
| Q38270717 | Optimizing IgG therapy in chronic autoimmune neuropathies: a hypothesis driven approach |
| Q34109136 | Overview of the pathogenesis and treatment of chronic inflammatory demyelinating polyneuropathy with intravenous immunoglobulins |
| Q34409385 | Pathogenesis and treatment of immune-mediated neuropathies |
| Q84019047 | Peripheral neuropathies: Establishing common clinical research standards for CIDP |
| Q50748736 | Pharmacokinetics and Pharmacodynamics of Intravenous Immunoglobulin G Maintenance Therapy in Chronic Immune-mediated Neuropathies. |
| Q84411545 | Pharmacokinetics and safety of subcutaneous immune globulin (human), 10% caprylate/chromatography purified in patients with primary immunodeficiency disease |
| Q34344264 | Placebo-controlled trial of rituximab in IgM anti-myelin-associated glycoprotein neuropathy |
| Q37686735 | Plasma exchange and immunoadsorption for autoimmune neurologic diseases - current guidelines and future perspectives |
| Q37807823 | Plasma exchange and intravenous immunoglobulins: Mechanism of action in immune-mediated neuropathies |
| Q27320796 | Predicting the Response to Intravenous Immunoglobulins in an Animal Model of Chronic Neuritis |
| Q43172858 | Pulsed high-dose dexamethasone versus standard prednisolone treatment for chronic inflammatory demyelinating polyradiculoneuropathy (PREDICT study): a double-blind, randomised, controlled trial |
| Q64905014 | Quantitative grip force assessment of muscular weakness in chronic inflammatory demyelinating polyneuropathy. |
| Q92904400 | Randomized, controlled crossover study of IVIg for demyelinating polyneuropathy and diabetes |
| Q26864907 | Rapid and reversible responses to IVIG in autoimmune neuromuscular diseases suggest mechanisms of action involving competition with functionally important autoantibodies |
| Q64118005 | Restabilization treatment after intravenous immunoglobulin withdrawal in chronic inflammatory demyelinating polyneuropathy: Results from the pre-randomization phase of the Polyneuropathy And Treatment with Hizentra study |
| Q90624866 | Review process for IVIg treatment: Lessons learned from INSIGHTS neuropathy study |
| Q43114504 | Rituximab in treatment-resistant CIDP with antibodies against paranodal proteins. |
| Q35858046 | Rituximab induces sustained reduction of pathogenic B cells in patients with peripheral nervous system autoimmunity. |
| Q40081746 | Severe refractory CIDP: a case series of 10 patients treated with bortezomib. |
| Q36266469 | Sialylation of IgG Fc domain impairs complement-dependent cytotoxicity |
| Q48202440 | Spinal anesthesia for cesarean section in a patient with chronic inflammatory demyelinating polyradiculoneuropathy |
| Q41834761 | Standard and escalating treatment of chronic inflammatory demyelinating polyradiculoneuropathy |
| Q50085719 | Subcutaneous IgG for chronic inflammatory demyelinating polyneuropathy |
| Q91972845 | Subcutaneous Immunoglobulin in Infantile Chronic Inflammatory Demyelinating Polyneuropathy: A Case Report |
| Q47419841 | Subcutaneous immunoglobulin for maintenance treatment in chronic inflammatory demyelinating polyneuropathy (PATH): a randomised, double-blind, placebo-controlled, phase 3 trial |
| Q37125900 | Subcutaneous immunoglobulin for maintenance treatment in chronic inflammatory demyelinating polyneuropathy (The PATH Study): study protocol for a randomized controlled trial |
| Q84468963 | Subcutaneous immunoglobulin therapy for the treatment of multifocal motor neuropathy: a case report |
| Q37626132 | Subcutaneous immunoglobulin: opportunities and outlook |
| Q26745685 | Subcutaneous immunoglobulins in the treatment of chronic immune-mediated neuropathies |
| Q37247076 | Terminal complement activation is increased and associated with disease severity in CIDP |
| Q37381546 | The Importance of Rare Subtypes in Diagnosis and Treatment of Peripheral Neuropathy: A Review. |
| Q38817738 | The Role of Peripheral Myelin Protein 2 in Remyelination |
| Q35107092 | The characteristics of chronic inflammatory demyelinating polyneuropathy in patients with and without diabetes--an observational study |
| Q26743993 | The dilemma of diabetes in chronic inflammatory demyelinating polyneuropathy |
| Q26772148 | The epidemiology and risk factors of chronic polyneuropathy |
| Q37237413 | The role of IVIg in autoimmune neuropathies: the latest evidence |
| Q41170285 | Therapeutic Potential of Intravenous Immunoglobulin in Acute Brain Injury |
| Q92187412 | Treatment Patterns and Costs of Chronic Inflammatory Demyelinating Polyneuropathy: A Claims Database Analysis |
| Q85032476 | Treatment of Chronic Inflammatory Demyelinating Polyneuropathy |
| Q85207803 | Treatment of chronic inflammatory demyelinating polyneuropathy |
| Q37557375 | Treatment of chronic inflammatory demyelinating polyneuropathy: from molecular bases to practical considerations. |
| Q48387989 | Treatment of neurological autoimmune diseases with immunoglobulins: first insights from the prospective SIGNS registry |
| Q36737563 | Treatment of patients with multifocal motor neuropathy with immunoglobulins in clinical practice: the SIGNS registry |
| Q30397454 | Treatments for chronic inflammatory demyelinating polyradiculoneuropathy (CIDP): an overview of systematic reviews. |
| Q64080054 | Two comparative assessments of intravenous immunoglobulin therapy switching patterns in the treatment of chronic inflammatory demyelinating polyneuropathy in the US |
| Q42372439 | Two years' long-term follow up in chronic inflammatory demyelinating polyradiculoneuropathy: efficacy of intravenous immunoglobulin treatment |
| Q86421387 | Use of immunoglobulin (Ig) in peripheral neuropathies. Impact of Ig on remission rates: comparison of intravenous immunoglobulin and subcutaneous immunoglobulin |
| Q33616530 | Vibratory thresholds and mobility in older persons |
| Q34409057 | What are the Therapeutic Advances in Neurology? Opinions from World Experts. |
| Q84475530 | [Administration of intravenous immunoglobulins in neurology. An evidence-based consensus: update 2010] |
| Q81741355 | [Current use of immunoglobulins in neurology] |
| Q84093786 | [From Guillain-Barré syndrome to chronic inflammatory polyneuropathies in childhood] |
| Q83179107 | [The significance of intravenous immunoglobulin in treatment of immune-mediated polyneuropathies] |
Search more.